Navigation Links
Pharmacyclics Files Schedule 14D-9 Statement with Securities and Exchange Commission
Date:5/14/2008

SUNNYVALE, Calif., May 14 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that it has filed a Schedule 14D-9 Solicitation/Recommendation Statement with the Securities and Exchange Commission (the "Commission"), as required by the Commission's rules, in response to an unsolicited tender offer (the "Offer") by RWD Acquisition I LLC (the "Purchaser") to purchase up to 4 million shares of the common stock of Pharmacyclics, Inc. (the "Company") for $1.05 per share. The terms and conditions of the Offer are set forth in an Offer to Purchase and the related Letter of Transmittal (collectively, the "Offer to Purchase") filed with the Commission by the Purchaser on May 1, 2008. Robert W. Duggan, one of the Company's principal stockholders and a member of the Company's board of directors (the "Board") is the sole member of Purchaser.

The Board is expressing no opinion to the Company's stockholders and is remaining neutral with respect to the Offer. The Board has not made a determination whether the Offer is fair to or in the best interests of the Company's stockholders and is not making a recommendation regarding whether the Company's stockholders should accept the Offer and tender their Shares, and if so how many shares to tender, or reject the Offer and not tender their Shares. The Company believes that a stockholder's decision on whether or not to tender shares in the Offer and, if so, how many shares to tender, is a personal investment decision based upon each individual stockholder's particular circumstances. The Company believes that each stockholder should review the Offer, consult with such holder's financial, tax and accounting advisors and make an independent determination.

This press release is neither an offer to purchase nor a solicitation of an offer to sell securities of Pharmacyclics, Inc. Stockholders are advised to make their own decisions on whether to tender their shares and accept the Offer, based on all of the available information, including the factors considered by the Board. These factors are described in the Company's Schedule 14D-9, filed today with the Commission. The Schedule 14D-9 and the Offer to Purchase contain important information that should be read carefully before any decision is made with respect to the Offer. Stockholders can receive copies of such documents free of charge at the SEC's web site, http://www.sec.gov. The Purchaser has stated that copies of the Offer to Purchase will be made available at Purchaser's expense. Stockholders who wish to receive copies of the Offer to Purchase should contact MacKenzie Partners, Inc., the information agent for the Offer, collect at (212) 929-5500 or toll- free at (800) 322-2885. Stockholders may also obtain free copies of the Company's Schedule 14D-9 and other documents filed with the Commission by contacting Leiv Lea, Vice President, Finance and Administration and Chief Financial Officer and Secretary, in writing at 995 East Arques Avenue, Sunnyvale, California 94085 or by telephone at (408) 774-0330.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R), and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmacyclics Reports Third Quarter 2008 Financial Results
2. Pharmacyclics Announces Conference Call to Discuss Third Quarter 2008 Financial Results
3. Pharmacyclics Announces Conference Call to Discuss Second Quarter 2008 Financial Results
4. Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
5. Castle Connollys Long Islands Top Doctors Published in Newsday Generates More Than 1.1 Million Views of Top Doctors Profiles in Single Day
6. The Quantum Group Files Four Additional Patents
7. Phyhealth Files Historical Financials With the Pink Sheets and Takes Next Step Toward Becoming Fully Reporting
8. Laser Energetics Files Patent Application for a New BrightStar(TM) Alexandrite Laser
9. Penn Treaty Files 2006 Form 10-K
10. Retail Industry Leaders Association Files Amicus in California Health Care Litigation
11. Conseco Files 10-K and Sets Earnings Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Jessica Barron, of ... is now accepting new dental patients and families in the North Metro Denver area. ... services from cleanings to cosmetic dentistry, and all in the most relaxing environment. , ...
(Date:2/10/2016)... ... ... Gout is like no other joint pain. It strikes suddenly, like flicking on ... redness. It is triggered by the crystallization of uric acid within the joints. It ... to the February 2016 issue of Harvard Men's Health Watch. , The large joint ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged ... Research shows that the Goal Attainment Scale (GAS) captures 20% more change in ... learn more about the Goal Attainment Scale, Education Resources Inc. is offering a ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... make Everseat digital self-scheduling readily available to physicians. The integration will ... can find and select appointments via Everseat’s free mobile app. , The partnership ...
(Date:2/10/2016)... ... ... Workrite Ergonomics, who is celebrating their 25th year of business in 2016, ... internationally recognized leader in their industry. , "We are very proud of our heritage ... “Workrite recognized the importance of good ergonomics before most of our competition even ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 10, 2016   Genomic Health, Inc. (Nasdaq: GHDX ... and year ended December 31, 2015. --> ... of 2015, compared with $69.1 million in the fourth quarter of ... revenue increased 9 percent compared with the same period in the ... revenue was $63.9 million in the fourth quarter of 2015, an ...
(Date:2/10/2016)... Calif. , Feb. 10, 2016  Cepheid ... Warren Kocmond , formerly Executive Vice President and ... position of President and Chief Operating Officer.  In ... expanded, and now include Global Commercial Operations in ... Customer Service.  Mr. Kocmond will continue to report ...
(Date:2/10/2016)... och PITTSBURGH , 10 ... inte, och detta pressmeddelande får inte distribueras, ... till, och inga anmälningssedlar kommer att accepteras ... något land där Erbjudandet, distribution av detta ... skulle strida mot tillämpliga lagar eller regler ...
Breaking Medicine Technology: